Eloxx Pharmaceuticals (ELOX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends ELOX vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Eloxx Pharmaceuticals vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community believe in ATNFW or ELOX? Eloxx Pharmaceuticals received 13 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AEloxx PharmaceuticalsOutperform Votes1343.33% Underperform Votes1756.67% Do institutionals and insiders have more ownership in ATNFW or ELOX? 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, ATNFW or ELOX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AEloxx PharmaceuticalsN/AN/A-$36.06MN/AN/A Is ATNFW or ELOX more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Eloxx Pharmaceuticals N/A N/A N/A Does the media refer more to ATNFW or ELOX? In the previous week, 180 Life Sciences had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Eloxx Pharmaceuticals. 180 Life Sciences' average media sentiment score of 1.89 beat Eloxx Pharmaceuticals' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Eloxx Pharmaceuticals Neutral SummaryEloxx Pharmaceuticals beats 180 Life Sciences on 3 of the 5 factors compared between the two stocks. Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELOX vs. The Competition Export to ExcelMetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.05B$5.56B$9.10BDividend YieldN/A1.84%5.32%3.99%P/E RatioN/A46.5190.3018.28Price / SalesN/A319.021,251.4080.65Price / CashN/A190.0245.9637.70Price / BookN/A4.125.124.70Net Income-$36.06M-$40.99M$111.33M$224.47M Eloxx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0030ATNFW180 Life SciencesN/A$0.01+2.3%N/A+350.0%$0.00N/A0.007Gap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.03-1.0%N/A+11.1%$0.00N/A0.002AIMDWAinosN/A$0.10-43.3%N/A+71.7%$0.00$40,633.000.0040ALVOWAlvotechN/A$2.84-3.4%N/A-45.3%$0.00$391.87M0.004Short Interest ↓Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.06flatN/A+5.2%$0.00N/A0.004BFRIWBiofronteraN/A$0.06-1.1%N/AN/A$0.00$35.36M0.0070BTMDWbioteN/A$0.44-11.2%N/AN/A$0.00$193.06M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.14+0.1%N/A-90.6%$0.00N/A0.008Short Interest ↑CELUWCelularityN/A$0.06-21.0%N/A+120.5%$0.00$48.20M0.00220Gap DownHigh Trading Volume Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Celularity Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELOX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
